(Q43855578)

English

Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis

scientific article published in January 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

P Ravn

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

G Neugebauer

2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

C Christiansen

3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2002

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

320-324

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900665-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900665-2

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900665-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bisphosphonates: mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900665-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900665-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Noninvasive assessment of bone mineral and structure: state of the art.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900665-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bisphosphonate effects and the bone remodeling transient.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900665-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved determination of the bisphosphonate alendronate in human plasma and urine by automated precolumn derivatization and high-performance liquid chromatography with fluorescence and electrochemical detection

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900665-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900665-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900665-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900665-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900665-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900665-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900665-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900665-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S8756-3282(01)00665-2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43855578&oldid=2143573521"